In Vitro Activities of Mupirocin, Tigecycline, Ceftaroline, Vancomycin, Linezolid and Daptomycin in Clinical Isolates of Methicillin-Resistant Staphylococcus aureus by E-Test Methodology
Read full paper at:
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=54074#.VOBgLizQrzE
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=54074#.VOBgLizQrzE
Author(s)
Affiliation(s)
1Bronx High School of Science, Bronx, NY, USA.
2The Dr. James J. Rahal Jr. Division of Infectious Diseases, New York Hospital Queens, Flushing, NY, USA.
3Department of Pathology, New York Medical College, Valhalla, NY, USA.
4Weill Cornell Medical College, Cornell University, Ithaca, USA.
2The Dr. James J. Rahal Jr. Division of Infectious Diseases, New York Hospital Queens, Flushing, NY, USA.
3Department of Pathology, New York Medical College, Valhalla, NY, USA.
4Weill Cornell Medical College, Cornell University, Ithaca, USA.
ABSTRACT
Introduction: In 2013, the Center for Disease Control (CDC) designated methicillin-resistant Staphylococcus aureus
(MRSA) as a serious threat. In addition to its intrinsic virulence,
MRSA has become resistant to numerous antibacterial agents. In many
instances, mupirocin is used empirically to decolonize patients
harboring MRSA to decrease the possibility of progression to disease. In vitro
susceptibility information is critical to identify patients who would
benefit from use of mupirocin for decolonization and treatment of
infections caused by MRSA. Methods: One-hundred and sixty-three recent
MRSA single patient clinical isolates were collected from the Clinical
Microbiology Laboratory. In-vitro susceptibility testing was
performed using E-test methodology for tigecycline, ceftaroline,
daptomycin, vancomycin, linezolid, and mupirocin. Results: Of the 163
MRSA isolates tested, >99% demonstrated susceptibility to
tigecycline, ceftaroline, daptomycin, vancomycin, and linezolid. Seventy
(43%) had vancomycin MICs ≥ 1.5 μg/ml, twenty-four isolates (15%) were
resistant to mupirocin, and three appeared to express mupirocin
hetero-resistance. Conclusion: While antibiotic susceptibility to
mupirocin is not routinely performed in clinical microbiology
laboratories, the level of resistance to mupirocin identified in this
surveillance study suggests that susceptibility testing should be added
to routine MRSA panels.
KEYWORDS
Methicillin-Resistant Staphylococcus aureus, Mupirocin Resistance, Antibiotic Susceptibility, MIC Creep
Cite this paper
References
Chadha, P. , Mariano, N. , LaBombardi, V. , Segal-Maurer, S. and Urban, C. (2015) In Vitro
Activities of Mupirocin, Tigecycline, Ceftaroline, Vancomycin,
Linezolid and Daptomycin in Clinical Isolates of Methicillin-Resistant Staphylococcus aureus by E-Test Methodology. Open Journal of Medical Microbiology, 5, 12-16. doi: 10.4236/ojmm.2015.51002.
| [1] | Stryjewski,
M.E. and Corey G.R. (2014) Methicillin-Resistant Staphylococcus: An
Evolving Pathogen. Clinical Infectious Diseases, 58, S10-S19. http://dx.doi.org/10.1093/cid/cit613 |
| [2] | Greenlee-Wacker, M., DeLeo, F.R. and Nauseef W.M. (in Press) How Methicillin-Resistant Staphylococcus aureus Evade Neutrophil Killing. Current Opinion in Hematology. |
| [3] | CDC. http://www.cdc.gov/drugresistance/threat-report-2013/pdf |
| [4] | Sievert,
D.M., Ricks, P., Edwards, J.R., Schneider, A., Patel, J., Srinivasan,
A., Kallen, A., Limbago, B. and Fridkin, S. (2013)
Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated
Infections: Summary of Data Reported to the National Healthcare Safety
Network at the Centers for Disease Control and Prevention, 2009-1020.
Infection Control Hospital Epidemiology, 34, 1-14. http://dx.doi.org/10.1086/668770 |
| [5] | Clinical and Laboratory Standards Institute (2013) Performance Standards for Antimicrobial Susceptibility Testing; 23rd Informational Supplement. CLSI Document M100-S23, Clinical and Laboratory Standards Institute, Wayne. |
| [6] | Cookson,
B.D. (1998) The Emergence of Mupirocin Resistance: A Challenge to
Infection Control and Antibiotic Prescribing Practice. Journal of
antimicrobial Chemotherapy, 41, 11-18. http://dx.doi.org/10.1093/jac/41.1.11 |
| [7] | Zimlichman,
E., Henderson, D., Tamir, O., Franz, C., Song, P., Yamin, C.K.,
Keohane, C., Denham, C.R. and Bates, D.W. (2013) Healthcare-Associated
Infections: A Meta-Analysis of Costs and Financial Impact on the US
Health Care System. JAMA Internal Medicine, 173, 2039-2046. http://dx.doi.org/10.1001/jamainternmed.2013.9763 |
| [8] | Scott, R.D. (2009) The Direct Medical Costs of Healthcare-Associated Infections in US Hospitals and the Benefits of Prevention. http://www.cdc.gov/hai/pdfs/hai/scott_costpaper.pdf |
| [9] | Sader,
H.S., Fey, P.D., Fish, D.N., Limaye, A.P., Pankey, G., Rahal, J.,
Rybak, M.J., Snydman, D.R., Steed, L.L., Waites, K. and Jones, R.N.
(2009) Evaluation of Vancomycin and Daptomycin Potency Trends (MIC
Creep) against Methicillin-Resistant Staphylococcus aureus Isolates
Collected in Nine US Medical Centers from 2002 to 2006. Antimicrobial
Agents and Chemotherapy, 53, 4127-4132. http://dx.doi.org/10.1128/AAC.00616-09 |
| [10] | Jacob, J.T. and DiazGranados, C.A. (2013) High Vancomycin Minimum Inhibitory Concentration and Clinical Outcomes in Adults with Methicillin-Resistant Staphylococcus aureus Infections: A Meta-Analysis. International Journal of Infectious Diseases, 17, e93-e100. |
| [11] | Sakoulas,
G., Moise-Broder, P.A., Schentag, J., Forrest, A., Moellering Jr., R.C.
and Eliopoulos, G.M. (2004) Relationship of MIC and Bactericidal
Activity to Efficacy of Vancomycin for Treatment of
Methicillin-Resistant Staphylococcus aureus Bacteremia. Journal of
Clinical Microbiology, 42, 2398-2402. http://dx.doi.org/10.1128/JCM.42.6.2398-2402.2004 |
| [12] | Brink,
A.J. (2012) Does Resistance in Se-vere Infections Caused by
Methicillin-Resistant Staphylococcus aureus Give You the “Creeps”?
Current Opinion in Critical Care, 18, 451-459. http://dx.doi.org/10.1097/MCC.0b013e3283578968 |
| [13] | Bland,
C.M., Porr, W.H., Davis, K.A. and Mansell, K.B. (2010) Vancomycin MIC
Susceptibility Testing of Methicillin-Susceptible and
Methicillin-Resistant Staphylococcus aureus Isolates: A Comparison
between Etest® and an Automated Testing Method. Southern Medical
Journal, 103, 1124-1128. http://dx.doi.org/10.1097/SMJ.0b013e3181efb5b1 |
| [14] | Arunava, K., Selvaraj, S., Sivaraman, U., Shailesh, K., Noyal, M.J. and Sreenivasan, S. (2013) Changing Trends in Resistance Pattern of Methicillin Resistant Staphylococcus aureus. Journal of Clinical and Diagnostic Research, 7, 1979-1982. |
| [15] | Richter,
S.S., Diekema, D.J., Heilmann, K.P., Dohrn, C.L., Crispell, E.K.,
Riahi, F., McDanel, J.S., Satola, S.W. and Doern, G.V. (2014) Activities
of Vancomycin, Ceftaroline, and Mupirocin against Staphylococcus aureus
Isolates Collected in a 2011 National Surveillance Study in the United
States. Antimicrobial Agents and Chemotherapy, 58, 740-745. http://dx.doi.org/10.1128/AAC.01915-13 |
| [16] | Lee,
H., Lim, H., Bae, I.K., Yong, D., Jeong, S.H., Lee, K. and Chong, Y.
(2013) Co-Existance of Mupirocin and Antiseptic Resistance in
Methicillin-Resistant Staphylococcus aureus Isolates from Korea.
Diagnostic Microbiology and Infectious Disease, 75, 308-312. http://dx.doi.org/10.1016/j.diagmicrobio.2012.11.025 |
| [17] | Woodford,
N., Afzal-Shah, M., Warner, M. and Livermore, D.M. (2008) In Vitro
Activity of Retapamulin against Staphylococcus aureus Isolates Resistant
to Fusidic Acid and Mupirocin. Journal of Antimicrobial Chemotherapy,
62, 766-768. http://dx.doi.org/10.1093/jac/dkn266 |
| [18] | Patel, J.B., Gorwitz, R.J. and Jernigan, J.A. (2009) Mupirocin Resistance. Clinical Infectious Diseases, 49, 935-941. http://dx.doi.org/10.1086/605495 |
| [19] | Schweizer,
M.L. and Herwaldt, L.A. (2012) Surgical Site Infections and Their
Prevention. Current Opinion in Infectious Disease, 25, 378-384. http://dx.doi.org/10.1097/QCO.0b013e32835532f7 |
| [20] | van
Rijen, M.M.L., Bonten, M., Wenzel, R.P. and Kluytmans, J.A.J.W. (2008)
Intranasal Mupirocin for Reduction of Staphylococcus aureus Infections
in Surgical Patients with Nasal Carriage: A Systematic Review. Journal
of Antimicrobial Chemotherapy, 61, 254-261. http://dx.doi.org/10.1093/jac/dkm480 |
| [21] | Robotham,
J.V., Graves, N., Cookson, B.D., Barnett, A.G., Wilson, J.A.,
Edgeworth, J.D., Batra, R., Cuthbertson, B.H. and Cooper, B.S. (2011)
Screening, Isolation, and Decolonization Strategies in the Control of
Methicillin Resistant Staphylococcus aureus in Intensive Care Units:
Cost Effectiveness Evaluation. British Medical Journal, 343, Article ID:
d5694. http://dx.doi.org/10.1136/bmj.d5694 |
| [22] | Courville,
X.F., Tomek, I.M., Kirkland, K.B., Birhle, M., Kantor, S.R. and
Finlayson, S.R.G. (2012) Cost-Effectiveness of Preoperative Nasal
Mupirocin Treatment in Preventing Surgical Site Infection in Patients
Undergoing Total Hip and Knee Arthroplasty: A Cost-Effectiveness
Analysis. Infection Control and Hospital Epidemiology, 33, 152-159. http://dx.doi.org/10.1086/663704 |
| [23] | Goldsack,
J.C., DeRitter, C., Power, M., Spencer, A., Taylor, C.L., Kim, S.F.,
Kirk, R. and Drees, M. (2014) Clinical, Patient Experience and Cost
Impacts of Performing Active Surveillance on Known Methicillin-Resistant
Staphylococcus aureus Positive Patients Admitted to Medical-Surgical
Units. American Journal of Infection Control, 42, 1039-1043. http://dx.doi.org/10.1016/j.ajic.2014.07.011 |
| [24] | Huang,
S.S., Septimus, E., Avery, T.R., Lee, G.M., Hickok, J., Weinstein,
R.A., Moody, J., Hayden, M.K., Perlin, J.B., Platt, R. and Ray, G.T.
(2014) Cost Savings of Universal Decolonization to Prevent Intensive
Care Unit Infection: Implications of the REDUCE MRSA Trial. Infection
Control Hospital Epidemiology, 35, S23-S31. http://dx.doi.org/10.1086/677819 |
| [25] | Livermore,
D.M. and Pearson, A. (2007) Antibiotic Resistance: Location, Location,
Location. Clinical Microbiology and Infection, 13, 7-16. http://dx.doi.org/10.1111/j.1469-0691.2007.01724.x eww150215lx |
评论
发表评论